Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis

Zaffuto, Emanuele; Pompe, Raisa S.; Zanaty, Marc; Bondarenko, Helen Davis; Leyh-Bannurah, Sami-Ramzi; Moschini, Marco; Dell’Oglio, Paolo; Gandaglia, Giorgio; Fossati, Nicola; Stabile, Armando; Zorn, Kevin C.; Montorsi, Francesco; Briganti, Alberto; Karakiewicz, Pierre I.

doi:10.1016/j.clgc.2017.04.006

Cited by 54 publications

(38 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rarity of primary NEPC means that most available studies to date have been case reports . Zaffuto et al and Alanee et al explored the differences in prognostic and clinical data between patients with the small‐cell carcinoma (SCC) subtype of NEPC and those with non‐SCC NEPC. SCC had a poorer prognosis with a median survival time of 10 months, compared with 12 months in patients with non‐SCC NEPC.…”

Section: Introductionmentioning

confidence: 99%

“…The rarity of primary NEPC means that most available studies to date have been case reports. [7][8][9][10][11] Zaffuto et al 12 Although the difference between the median survival times was statistically significant, this did not translate into a notable clinical difference. Most T-SCNCs present initially as prostate adenocarcinomas, which then undergo neuroendocrine (NE) differentiation.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Low‐serum prostate‐specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer

Wang

Abudurexiti

et al. 2019

The Prostate

View full text Add to dashboard Cite

Background The rarities of primary neuroendocrine prostate cancer (NEPC) and primary adenocarcinoma with neuroendocrine differentiation (NE differentiation) mean that their clinical characteristics have not been fully elucidated. Materials and Methods A total of 449 patients with NEPC, including 352 cases of pure NEPC and 97 cases of NE differentiation, together with 408 629 cases of prostate adenocarcinoma at diagnosis were retrieved from the Surveillance, Epidemiology, and End Results program (2010‐2015). Clinical parameters and prognoses were compared between patients with different histological types of NEPC using the χ2 test and Kaplan‐Meier analysis, respectively. The prognostic value of prostate‐specific antigen (PSA) in NEPC and adenocarcinoma was evaluated using Cox regression and the Kaplan‐Meier method. Results Pure NEPC had higher rates of visceral metastases (brain, lung, and liver: 4.58%, 26.72%, and 36.64%, respectively) but a lower rate of bone metastasis (65.65%) compared with NE differentiation and prostate adenocarcinoma. Moreover, patients diagnosed with pure NEPC had a poorer outcome (median survival time: 10 months) compared with patients with NE differentiation (26 months) and prostate adenocarcinoma (median survival time not reached). Using PSA 4.1 to 10 ng/mL as the reference, the adjusted hazard ratios (HRs) for PSA lower than or equal to 4.0 ng/mL were 2.24 (95% confidence interval [CI]: 1.11‐4.55, P = .025) in the NE differentiation group and 1.57 (95% CI: 1.11‐2.23, P = .011) in the pure NEPC group. Conclusions Patients with NE differentiation had different clinical characteristics and a better prognosis than patients with pure NEPC. In addition, low‐serum PSA levels were associated with a poorer prognosis in patients with either NEPC or NE differentiation.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Low‐serum prostate‐specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer

Wang

Abudurexiti

et al. 2019

The Prostate

View full text Add to dashboard Cite

show abstract

“…Prostate cancer is the second most common malignancy in males and the second urological tumor associated with paraneoplastic manifestations after renal cell carcinoma ( 9 ). The vast majority are adenocarcinomas, while only 0.5% of tumors are classified as neuroendocrine ( 10 ). Among them, the occurrence of LCNPC is extremely rare, described only in case reports.…”

Section: Discussionmentioning

confidence: 99%

Co-occurrence of Dermatomyositis and Polycythemia Unveiling Rare de Novo Neuroendocrine Prostate Tumor

et al. 2018

View full text Add to dashboard Cite

We present a case of dermatomyositis together with polycythemia as initial manifestations of a particularly rare type of prostate cancer. A 69-year-old man was hospitalized for facial erythema and symptoms of fatigue. Physical evaluation, serum creatinine phosphokinase and electromyography were consistent with dermatomyositis. In parallel, the hemoglobin level was 18.5 g/dL, serum erythropoietin levels were low normal and no JAK2 mutation was found. Given a strong suspicion of a paraneoplastic syndrome the patient underwent abdominal computed tomography revealing a prostate mass, enlarged iliac lymph nodes and a fracture of L1 due to metastasis. The unusual paraneoplastic manifestations prompted a more thorough immunohistologic examination of the needle biopsy specimen taken from the prostate, which led to the diagnosis of large cell neuroendocrine prostate carcinoma. It is a most rare type of prostate cancer, carrying a poor prognosis. To our knowledge, this is the first case in the literature associating a neuroendocrine cancer of the prostate with dermatomyositis.

show abstract

“…Small‐cell prostate carcinoma (SCPC) is a rare but highly aggressive malignancy . Unlike prostate adenocarcinoma, SCPC tends not to express classic prostate cancer markers such as androgen receptor (AR), but frequently expresses the neuroendocrine markers chromogranin A (CHGA) and synaptophysin (SYP) instead .…”

Section: Introductionmentioning

confidence: 99%

“…Consequently, patients are managed similarly to those with other pulmonary and extrapulmonary small‐cell carcinomas, with platinum‐based chemotherapy. Durable responses are unusual, and life‐expectancy is <1 year .…”

Section: Introductionmentioning

confidence: 99%

Biallelic tumour suppressor loss and DNA repair defects in de novo small‐cell prostate carcinoma

Chedgy

Vandekerkhove

Herberts

et al. 2018

The Journal of Pathology

View full text Add to dashboard Cite

Small-cell prostate carcinoma (SCPC) is an aggressive malignancy that is managed similarly to small-cell lung cancer. SCPC can evolve from prostate adenocarcinoma in response to androgen deprivation therapy, but, in rare cases, is present at initial cancer diagnosis. The molecular aetiology of de novo SCPC is incompletely understood, owing to the scarcity of tumour tissue and the short life-expectancy of patients. Through a retrospective search of our regional oncology pharmacy database, we identified 18 patients diagnosed with de novo SCPC between 2004 and 2017. Ten patients had pure SCPC pathology, and the remainder had some admixed adenocarcinoma foci, but all were treated with first-line platinum-based chemotherapy. The median overall survival was 28 months. We performed targeted DNA sequencing, whole exome sequencing and mRNA profiling on formalin-fixed paraffin-embedded archival tumour tissue. We observed frequent biallelic deletion and/or mutation of the tumour suppressor genes TP53, RB1, and PTEN, similarly to what was found in treatment-related SCPC. Indeed, at the RNA level, pure de novo SCPC closely resembled treatment-related SCPC. However, five patients had biallelic loss of DNA repair genes, including BRCA1, BRCA2, ATM, and MSH2/6, potentially underlying the high genomic instability of this rare disease variant. Two patients with pure de novo SCPC harboured ETS gene rearrangements involving androgen-driven promoters, consistent with the evolution of de novo SCPC from an androgen-driven ancestor. Overall, our results reveal a highly aggressive molecular landscape that underlies this unusual pathological variant, and suggest opportunities for targeted therapy strategies in a disease with few treatment options. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

show abstract

Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis

Cited by 54 publications

References 22 publications

Low‐serum prostate‐specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer

Low‐serum prostate‐specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer

Co-occurrence of Dermatomyositis and Polycythemia Unveiling Rare de Novo Neuroendocrine Prostate Tumor

Biallelic tumour suppressor loss and DNA repair defects in de novo small‐cell prostate carcinoma

Contact Info

Product

Resources

About